

21st Century Oncology
Radiation Therapy Services, Inc.

Br. 1

June 18, 2009

Licensing Assistance Team
Division of Nuclear Material Safety
U.S. Nuclear Regulatory Commission, Region I
475 Allendale Road
King of Prussia, PA 19406-1415

03037177

RE: Radioactive Material License # 09-31141-01

To Whom It May Concern:


We would like to request an amendment to the referenced Radioactive Materials License to include Anurag Chandra, M.D., as an Authorized User.

Dr. Chandra was listed as AU in City of New York Radioactive Materials License number 75-2955-01 (copy enclosed).

As supportive documentation, please find enclosed copy of letter from NYU Langone Medical Center attesting that Dr. Chandra was an authorized user approved by the Center's Medical Isotopes Committee, and copy of letter from MD Anderson cancer Center attesting that Dr. Chandra has satisfactory meet the training requirements specified in 10 CFR 35.490 and 35.690, including Nucletron device operation, safety procedures and clinical use.

Should you have any question regarding this application, feel free to call me at 239-768-7377.

Sincerely,



Daniel H. Galmarini, DABR
Director of Physics,

RECEIVED
REGION I
2009 JUN 22 PM 3:15

143816
NRC/REGNI MATERIALS-002

CITY OF NEW YORK RADIOACTIVE MATERIALS LICENSE

Pursuant to the New York City Charter and Article 175 of the New York City Health Code and in reliance on statements and representations heretofore made by licensee designated below, a license is hereby issued authorizing such licensee to transfer, receive, possess and use the radioactive material(s) designated below; and to use such radioactive materials for the purpose(s) and at the place(s) designated below. This license is subject to all applicable rules, regulations and orders now or hereafter in effect of all appropriate regulatory agencies and to any conditions specified below.

In accordance with Office of Radiological Health policy, License number 75-2955-01 is hereby amended to change Item 3b, Condition 29, to add Condition 30, and to read:

LICENSEE

1. Name: New York University
Hospitals Center

3a. License Number: 75-2955-01

2. Address: 550 First Avenue
New York, New York 10016

3b. Amendment Number: 12

4. Expiration Date: 28 February 2012

5. Reference Number: 86-96

6. Radioactive materials (element number)	7. Chemical and/or physical form	8. Maximum quantity licensee may possess at any one time
(A) Any radioactive material between atomic numbers 3 and 83, inclusive, except as listed below	(A) Any	(A) 18.5 Gigabecquerels each, except as listed below
(B) Molybdenum-99	(B) Generators with an active (i.e. not withdrawn or terminated) "New Drug Application" (NDA) approved by FDA	(B) 300 Gigabecquerels
(C) Technetium-99m	(C) Generators with an active (i.e. not withdrawn or terminated) "New Drug Application" (NDA) approved by FDA	(C) 300 Gigabecquerels
(D) Technetium-99m	(D) Pertechnetate	(D) 80 Gigabecquerels
(E) Iodine-131	(E) Any *****	(E) 200 Gigabecquerels

**CITY OF NEW YORK
RADIOACTIVE MATERIALS
LICENSE**

License Number: 75-2955-01

Amendment Number: 12

Reference Number: 86-96

6. Radioactive materials (element number)	7. Chemical and/or physical form	8. Maximum quantity licensee may possess at any one time
(F) Cesium-137	(F) Sealed Sources with an active (<i>i.e.</i> not withdrawn or terminated) "Safety Evaluation of Device" published in NRC "Registry of Radioactive Sealed Sources and Devices"	(F) 25 Gigabecquerels
(G) Fluorine-18	(G) Fluorodeoxyglucose F-18 Injection and F-18 Labeling	(G) 100 Gigabecquerels
(H) Cesium-137	(H) Sealed Sources (CIS-US Inc. Model #CEA-ORIS-LAPIB Model 437C)	(H) 130 Terabecquerels total, 3 sources of not more than 62.9 Terabecquerels each
(I) Cesium-137	(I) Sealed Sources (Nordion, Model C-3001)	(I) 98.05 Terabecquerels total, 2 sources of not more than 56.4 Terabecquerels each
(J) Strontium-90	(J) Sealed Source (PTW Model T-48012)	(J) 200 Megabecquerels
(K) Cobalt-57	(K) Sealed Sources with an active (<i>i.e.</i> not withdrawn or terminated) "Safety Evaluation of Device" published in NRC "Registry of Radioactive Sealed Sources and Devices"	(K) 24 Sources, none to exceed 925 Megabecquerels per source
(L) Barium-133	(L) Sealed Sources with an active (<i>i.e.</i> not withdrawn or terminated) "Safety Evaluation of Device" published in NRC "Registry of Radioactive Sealed Sources and Devices"	(L) 12 Sources, none to exceed 18.5 Megabecquerels per source
(M) Cesium-137	(M) Sealed Sources with an active (<i>i.e.</i> not withdrawn or terminated) "Safety Evaluation of Device" published in NRC "Registry of Radioactive Sealed Sources and Devices"	(M) 12 Sources, none to exceed 18.5 Megabecquerels per source
(N) Gadolinium-153	(N) Line Sources (North American Scientific, Inc., Model MED 3601) *****	(N) 67 Gigabecquerels total

**CITY OF NEW YORK
RADIOACTIVE MATERIALS
LICENSE**

License Number: 75-2955-01

Amendment Number: 12

Reference Number: 86-96

6. Radioactive materials (element number)	7. Chemical and/or physical form	8. Maximum quantity licensee may possess at any one time
(O) Iridium-192	(O) Sealed Sources (Varian Medical Systems, Model SL-777V and VS2000; Omnitron International, Model SL-777V)	(O) 1.924 Terabecquerels Total, 4 Sources not more than 481 Gigabecquerels each
(P) Germanium-68	(P) Sealed Sources (CTI Services, Inc. Line Sources and Uniformity Phantom)	(P) 250 Megabecquerels
(Q) Strontium-90	(Q) Sealed Source (Nuclear Enterprises, Model 2503-3)	(Q) 33 Megabecquerels
(R) Strontium-90	(R) Sealed Source (PTW, Model T48012)	(R) 200 Megabecquerels
(S) Gadolinium-153	(S) Sealed Sources (Isotope Products Laboratories, NES-8412; North American Scientific MED3601)	(S) 37 Gigabecquerels (No source to exceed 11.1 Gigabecquerels)
(T) Fluorine-18	(T) ¹⁸ F-AV-45 (AVID Radio-pharmaceuticals, Inc.)	(T) 3.7 Gigabecquerels
(U) Fluorine-18	(U) BAY 94-9172 (ZK6013443); Bayer Health Care Pharmaceuticals, Inc.	(U) 3.7 Gigabecquerels
(V) Iodine-131	(V) ¹³¹ I-TM 601 (Trans Molecular, Inc.) *****	(V) 11.1 Gigabecquerels

**CITY OF NEW YORK
RADIOACTIVE MATERIALS
LICENSE**

License Number: 75-2955-01

Amendment Number: 12


Reference Number: 86-96

**THE TOTAL POSSESSION LIMIT FOR ITEMS (A) THROUGH ITEMS (V) SHALL NOT EXCEED
234 TERABECQUERELS**

CONDITIONS

9. Authorized Use:

- (A) through (G), (T), (U), (V), Medical research, diagnosis and therapy (Broad Human-Use). Research involving the use of licensed material in or on human subjects may only be conducted if such material is covered by a current IND or NDA, or such research has the approval of the Institutional Review Board, the Medical Radiation Safety Committee, and a Radioactive Drug Research Committee (RDRC) authorized by FDA.
- (H) In a Model IBL-437C Irradiator for Biological Materials (manufactured by Compagnie ORIS Industrie and distributed by CIS-US, Inc.) for the irradiation of biological samples (Non-Human Use). To be used in Room 11N23, Bellevue Hospital Center.
- (I) In a MDS/Nordion Gammacell 3000 Elan-Type II Gamma Irradiator for the irradiation of biological samples (Non-Human Use). To be used in Room RRG19, Tisch Hospital, NYU Medical Center.
- (K) Flood calibration sources (Non-Human Use).
- (J), (L), (M), (P), (Q), (R) Calibration and quality control (Non-Human Use).
- (T) Under the strictures and conditions of FDA IND# 79,511.
- (U) Under the strictures and conditions of FDA IND# 78,868.
- (V) Under the strictures and conditions of FDA IND# 63,013.



**CITY OF NEW YORK
RADIOACTIVE MATERIALS
LICENSE**

License Number:	75-2955-01
Amendment Number:	12
Reference Number:	86-96

(N) and (S) For use in gamma cameras.

(O) In two (2) Varian Medical Systems, VariSource HDR Remote Afterloader Brachytherapy Units (but not the low-speed drive design of this model) for interstitial, intracavity, superficial, and bronchial treatment of cancer in humans. No source greater than 370 Gigabecquerels shall be installed in any unit. To be used in Room HC101, Tisch Hospital, NYU Medical Center, and in the New York University Medical Center Cancer Center.

10. The radioactive material may be used only at the New York University Hospitals Center campus bounded by E 30th Street, First Avenue, E 34th Street and the FDR Drive, at the Bellevue Hospital Center campus bounded by E 25th Street, First Avenue, E 30th Street and the FDR Drive, at the New York University Medical Center Cancer Center, 160 E. 34th Street, and at the Hospital for Joint Diseases, 301 East 17th Street; all of New York, New York.
11. The licensee shall comply with the provisions of Article 175 of the New York City Health Code entitled "Radiation Control."
12. Failure to pay the fee for inspection of a radioactive material site, upon notification from the Department, will result in termination of this license.
13. Radioactive materials shall be used by, or under the supervision of, individuals designated by the Radiation Safety Committee of New York University Medical Center and Bellevue Hospital Center, Manfred Blum, M.D., Chairman.
14. The radiation safety officer for this license is Steven Wagner, D.A.B.R.
15. The therapy physicists for this license are Jenghwa Chang, D.A.B.R., Keith De Wyngaert, D.A.B.R., Tamara Duckworth, D.A.B.R., Kerry Han, D.A.B.R., Christine Hitchen, D.A.B.R., Gabor Jozsef, D.A.B.R., and Roger Stevenson, D.A.B.R.
16. Radioactive material as sealed sources shall not be opened by the licensee.
17. The possession limit, when specified in Subitem 8, includes all radioactive material possessed by the licensee under this license whether in storage, implanted and/or inserted in hospitalized patients or otherwise in use.
18. The use of radioactive materials in or on humans shall be by, or under the supervision of, physicians.
19. Technetium-99m labeled sulfur colloid preparations which appear flocculent or aggregated shall not be used in humans.
20. The licensee shall establish written procedures for personnel performing tests to detect and quantify molybdenum-99 contamination.

These procedures shall include all necessary calculations and steps to be taken if activities of molybdenum-99 in excess of the limits specified in Section 175.103 of the New York City Health Code are detected.

Personnel performing tests to detect and quantify molybdenum-99 shall be given specific training in performing these tests prior to conducting such tests.

The licensee shall maintain for inspection by the Office of Radiological Health, results of each test performed to detect and quantify molybdenum-99 contamination and records of training given to personnel performing these tests. These records shall be maintained for three (3) years following the performance of these tests and the training of personnel.

**CITY OF NEW YORK
RADIOACTIVE MATERIALS
LICENSE**

License Number: 75-2955-01
Amendment Number: 12
Reference Number: 86-96

21. For individuals who open and/or prepare oral solutions of iodine-131 for therapeutic doses, surveys (e.g. measurement of iodine-131 in the thyroid gland of laboratory personnel and contamination surveys of personnel, equipment and facilities) shall be performed to determine compliance with Section 175.103(f)(3) of the New York City Health Code.
22. The following conditions apply for iodine-131 radiopharmaceutical therapy:
- (a) Patient release shall be based on either of the following conditions:
 - (1) The activity administered to the patient or the patient's calculated activity has decreased to less than 1.2 Gigabecquerel, or the measured maximum dose rate at a distance 1 meter from the patient is less than 0.07 mSv/hr.
 - (2) Measured and documented patient-specific parameters which otherwise result in compliance with the requirements of Section 175.103(c)(9) of the New York City Health Code.
 - (b) The radiation safety guidance required by Section 175.103(f)(3) of the New York City Health Code shall be provided by supplying the released patient, or the patient's competent representative, with both oral and written instructions on the risk of radiation and methods of reducing exposure to other individuals. The written instructions shall at least include the following items:
 - (1) The name and telephone number of a knowledgeable person to contact in the event the patient has any problems or questions.
 - (2) Information regarding the type of treatment given.
 - (3) Precautions regarding distances that should be maintained from other individuals, including separate sleeping arrangements.
 - (4) Precautions regarding minimizing time in public places.
 - (5) Precautions to reduce the spread of radioactive contamination (including, but not limited to, vomitus and urine).
 - (6) The length of time each of the precautions should be in effect.
 - (c) A "Record of Release" shall be maintained for each patient and shall contain at least the following items: activity at administration, any required decay calculations, date and time of patient release, copy of the patient's written instructions, and if required for patient release either patient's dose rate measurements (including the specific survey instrument used and the name of the individual performing the survey) or patient-specific parameters.
23. The following conditions apply for permanent brachytherapy implants:
- (a) Iodine-125 implant patient's release shall be based on either of the following conditions:
 - (1) The activity administered to the patient or the patient's calculated activity has decreased to less than 0.33 Gigabecquerel.
 - (2) The measured maximum dose rate at a distance 1 meter from the patient's target organ is less than 0.01 mSv/hr.

**CITY OF NEW YORK
RADIOACTIVE MATERIALS
LICENSE**

License Number:	75-2955-01
Amendment Number:	12
Reference Number:	86-96

- (b) Palladium-103 implant patient's release shall be based on either of the following conditions:
 - (1) The activity administered to the patient or the patient's calculated activity has decreased to less than 1.5 Gigabecquerel.
 - (2) The measured maximum dose rate at a distance 1 meter from the patient's target organ is less than 0.03 mSv/hr.
- (c) The radiation safety guidance required by Section 175.103(h)(3) of the New York City Health Code shall be provided by supplying the released patient, or the patient's competent representative, with both oral and written instructions on the risk of radiation and methods of reducing exposure to other individuals. The instructions shall at least include the following items:
 - (1) The name and telephone number of a knowledgeable person to contact in the event the patient has any problem or questions.
 - (2) A description of the size and number of implanted radioactive seeds.
 - (3) Specification of the length of time the patient should remain at specified distances from other individuals.
 - (4) That any bandages or linens that come into contact with the implant as well as the patient's urine voided through a provided strainer shall be examined for any seeds that have been released from the implant site. Any released seeds shall be handled with a provided tweezers and placed in a provided container away from other persons. The individual referred to in Subcondition (c)(1) above shall be notified in order to properly remove and dispose of any dislodged and/or urinated seeds.
- (d) A "Record of Release" shall be maintained for each patient which documents at least the following items: activity at administration, any required decay calculations, date and time of patient release, copy of patient's written instructions, and if required for patient release, patient's dose rate measurements including the specific survey instrument used and the name of the individual performing the survey.

24. The following subitems refer to the high dose rate remote afterloader brachytherapy units possessed by the licensee, henceforth referred to as the Unit (which presently are two (2) Varian Medical Systems VariSource HDR Remote Afterloader Brachytherapy Units):

- (a) All operators of the Unit other than authorized physician users must be New York State licensed radiation therapy technologists.
- (b) When treatments are performed with the Unit, only the patient shall be in the treatment room.
- (c) The Unit shall be labeled with the radiation symbol and the appropriate wording, "Caution" or "Danger" and "Radioactive Material".
- (d) The written instruction for operation and safety contained in the manufacturer's Instruction Manual shall be followed and a copy of these instructions shall be made available to each individual using or having responsibility for use of the Unit.
- (e) The Unit facility shall be provided with a system permitting continuous observation of the patient from outside the treatment room during patient irradiation. The patient shall be visually monitored during treatment.

**CITY OF NEW YORK
RADIOACTIVE MATERIALS
LICENSE**

License Number:	75-2955-01
Amendment Number:	12
Reference Number:	86-96

- (f) Daily (or on each day of use) checks of the Unit shall be performed to ascertain:
 - (1) Guide tubes are free of kinks or other imperfections.
 - (2) Reproducibility of source positioning within catheter to within \pm 1mm.
 - (3) Proper functioning of room interlocks.
 - (4) Proper functioning of source position indicators (e.g. lights, alarms, room monitor).

- (g) Written emergency instructions shall be posted at the Unit console. These instructions shall inform the Unit operator of the procedure to be followed should he/she be unable to return the source(s) to the shielded position with controls outside the treatment room. These instructions shall caution individuals to avoid exposure to the unshielded source(s) when in the treatment room and shall include specific instructions for:
 - (1) Locating and using the device for manually returning the source(s) to the shielded position.
 - (2) Removing the patient from the treatment room.
 - (3) Securing the room against unauthorized entry.
 - (4) Notifying the responsible physician or radiation safety officer.

- (h) Prior to initiation of a treatment program using the Unit and subsequent to each installation of iridium-192 source, radiation surveys and tests shall be performed in accordance with the following:
 - (1) A radiation survey shall be made of:
 - (i) The Unit's source housing with the iridium-192 source in the shielded position. The exposure rate shall not exceed the values specified in the Registry of Radioactive Sealed Sources and Devices.
 - (ii) All areas adjacent to the treatment room with the Unit's source in the treatment position. The survey shall be performed with a phantom and clearly establish:
 - (A) That radiation levels in restricted areas are not likely to cause personnel exposure in excess of the limits specified in Section 175.03(c) of the New York City Health Code.
 - (B) That radiation levels in unrestricted areas do not exceed the limits specified in Section 175.03(d) of the New York City Health Code.

**CITY OF NEW YORK
RADIOACTIVE MATERIALS
LICENSE**

License Number:	75-2955-01
Amendment Number:	12
Reference Number:	86-96

- (2) Tests shall be made to determine proper operation of:
 - (i) Electrical interlocks on entrance doors to the Unit treatment room.
 - (ii) The Unit's source shielded/unshielded indicators both at the source housing and on the control panel outside the treatment room.
 - (iii) The Unit's treatment timing device.
- (3) A report of the results of the above surveys and tests shall be sent to the Radioactive Materials Section, Office of Radiological Health, 2 Lafayette Street, 11th Floor, New York, New York 10007, not later than thirty (30) days following each installation of the Unit's source.
 - (i) Any changes made in treatment room shielding, location, or use of the Unit which could result in an increase in radiation levels in unrestricted areas outside of the treatment room and made subsequent to the completion of the initial radiation survey performed in accordance with Subitem (h) shall be evaluated by a radiation survey made in accordance with the requirements of Subitem (h)(1)(ii). A report describing the change(s) and giving the results of the survey(s), shall be sent to the Radioactive Materials Section, Office of Radiological Health, 2 Lafayette Street, 11th Floor, New York, New York 10007, not later than thirty (30) days following completion of the change(s).
 - (j) Each Unit shall be fully inspected and serviced during source replacement to assure proper functioning of the source exposure mechanism. This inspection and servicing shall be performed by Varian Medical Systems, or by persons specifically authorized to do so by the U.S. Nuclear Regulatory Commission or an Agreement State.
 - (k) The following shall be performed by Varian Medical Systems, or by persons specifically authorized to do so by the U.S. Nuclear Regulatory Commission or an Agreement State:
 - (1) Installation, relocation or removal of the Unit containing sources.
 - (2) Source exchange.
 - (3) Any maintenance or repair operations on the Unit involving work on any mechanism that could expose the source, reduce the shielding around the source, or compromise the safety of the Unit and result in increased radiation levels.
 - (l) Following source exchange and/or any source repairs and before its medical use, the licensee shall calibrate each iridium-192 sealed source in the Unit. The source output shall be determined to within an accuracy of ± 3 percent.
 - (m) The entrance to the room where the Unit is located shall be equipped with an electrical interlock system that will return the device's source to the shielded position immediately upon opening the entrance door. The interlock system shall be connected in such a manner that the device's source cannot be moved into the irradiation position until the treatment room entrance door is closed and the source "on-off" control is reset at the control panel.

**CITY OF NEW YORK
RADIOACTIVE MATERIALS
LICENSE**

License Number: 75-2955-01

Amendment Number: 12

Reference Number: 86-96

- (n) The Unit room shall be equipped with a radiation monitoring device which continuously monitors the source condition and is equipped with a back-up battery power supply for emergency operation. This device shall energize a visible signal to make the operator continuously aware of source condition in order that appropriate emergency procedures may be instituted to prevent unnecessary radiation exposure. Operating procedures shall require daily operational testing of the installed radiation monitor.

Whenever the continuous radiation monitoring device is not operational, any person entering the treatment room following an irradiation shall enter with an operable, calibrated radiation survey meter and shall determine the source condition.

- (o) Relocation of the Unit to a new location is not permitted without a license amendment from the New York City Department of Health. Following such amendment and relocation, a radiation survey shall be made and reported to the Office of Radiological Health within thirty (30) days after completion of the move.
- (p) Immediately after completing patient treatment with the Unit, the licensee shall conduct a radiation survey to ensure that the source has been removed from the patient. The area of use shall also be surveyed to ensure proper return of the source to the shielded position. The licensee shall make a record of each survey and retain the results for at least three (3) years.

25. The following conditions apply for the Compagnie ORIS Industrie Model IBL-437C Irradiator for Biological Materials:

- (a) The procedures contained in the instruction manuals for the device shall be followed and copies of these manuals shall be made available to each person using or having responsibility for use of the radioactive material.
- (b) The licensee shall not perform repairs or alterations of the irradiator involving removal of shielding or access to the licensed material. Removal, replacement and disposal of sealed sources in the irradiator shall be performed by a person specifically licensed by the U.S. Nuclear Regulatory Commission or an Agreement State to perform such services.
- (c) After installation of the irradiator and its cesium-137 sources and prior to the initiation of the irradiation programs, instrument surveys shall be conducted to determine radiation levels around, above and below the irradiator with the sources in the irradiate position and with the sources in the shielded position. A detailed report of the results of the survey shall be sent to the Radioactive Materials Division, Office of Radiological Health, 2 Lafayette Street, 11th Floor, New York, New York 10007, not later than thirty (30) days following the installation of the source(s).
- (d) The gamma irradiator operators shall wear a film badge at all times while on duty and an extremity radiation monitoring device (in the form of a ring dosimeter) when operating the irradiator.

**CITY OF NEW YORK
RADIOACTIVE MATERIALS
LICENSE**

License Number: 75-2955-01

Amendment Number: 12

Reference Number: 86-96


- 26. Conditions for use of tritium (more than 3.7 gigabecquerels in noncontained form):
 - (a) Individuals involved in operations which utilize, at any one time, more than 3.7 gigabecquerels of hydrogen-3 in a noncontained form (other than metallic foil) shall have bioassays performed within one (1) week following a single operation, and at weekly intervals for continuing operations.
 - (b) Tritium shall not be used in such a manner as to cause any individual to receive a radiation exposure such that urinary excretion rates exceed 740 kilobecquerels of tritium per liter when averaged over a calendar quarter.
 - (c) Urinalysis shall be performed at weekly intervals on all individuals who work in the restricted areas of facilities in which tritium is used. If the average concentration of tritium in urine for any single individual during a calendar quarter is less than 370 kilobecquerels per liter, urinalysis shall be performed on that individual at monthly intervals for the following calendar quarter and may continue at monthly intervals so long as the average concentration in the calendar quarter remains below 370 kilobecquerels per liter. The urine specimen shall be collected on the same day of the week insofar as possible.
 - (d) A report of an average concentration in excess of the limits specified in subitem c above for any individual shall be filed, in writing, within thirty (30) days of the end of the calendar quarter with the Radioactive Materials Division, Office of Radiological Health, 2 Lafayette Street, 11th Floor, New York, New York 10007. The report shall contain the results of all urinalyses for the individual during the calendar quarter, the cause of the excessive concentration and the corrective steps, taken or planned, to assure against recurrence.
 - (e) Any single urinalysis which discloses a concentration greater than 1.85 megabecquerels per liter shall be reported in writing, within seven (7) days of the licensee's receipt of the results, to the Radioactive Materials Division, Office of Radiological Health, 11th Floor, 2 Lafayette Street, New York, New York 10007.
- 27. Any radiopharmaceutical or radiobiologic with a current and active IND issued by FDA shall be used in accordance with Title 21, Part 312 of The Code of Federal Regulations or any successor regulation.
- 28. In addition to the possession limits in Item 8 and THE TOTAL POSSESSION LIMIT, the licensee shall further restrict the possession of unsealed radioactive materials of half-life greater than 120 days to quantities less than 10³ of the limits specified in Section 175.101(n)(4)(ii) of the New York City Health.
- 29. Each licensee who manufactures, transfers, receives, disassembles, or disposes of a nationally tracked source of Category I or Category II level as defined in 10 CFR §20.1003 shall complete and submit a National Source Tracking Transaction Report as specified in paragraphs (a) through (e) of 10 CFR §20.2207 for each type of transaction. Initial inventory reports must be submitted as described in paragraph (h). The reports must include information, be submitted in the time frame and in the manner specified, and be corrected as applicable as described in 10 CFR 20 §20.2207. The National Source Tracking System requirements - 10 CFR §20.1003 ([Nationally tracked source]Definitions), 10 CFR §20.2207 (Reports of transactions involving nationally tracked sources) and 10 CFR §20 Appendix E (Nationally Tracked Source Thresholds) - have been provided to each affected licensee, and are a document incorporated by reference as part of this license.

**CITY OF NEW YORK
RADIOACTIVE MATERIALS
LICENSE**

License Number: 75-2955-01
Amendment Number: 12
Reference Number: 86-96

30. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations and procedures contained in the documents including any enclosures listed below. Article 175 of the New York City Health Code shall govern unless the statements, representations and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- (A) Letter dated 16 January 2007
- (B) Application dated 19 January 2007
- (C) Letter with ancillary materials dated 23 February 2007
- (D) Letter dated 11 April 2007
- (E) Letter dated 8 January 2008
- (F) Letter dated 27 February 2008
- (G) Letter with ancillary documentation dated 4 August 2008
- (H) Letter dated 19 September 2008
- (I) National Source Tracking System Requirements -- 10 CFR §20.1003, 10 CFR §20.2207, and 10 CFR §20 Appendix E -- attachment dated 03/02/2009



MAR 17 2009

Date: _____
DPH/ih

**FOR THE NEW YORK CITY DEPARTMENT
OF HEALTH AND MENTAL HYGIENE**

Daniel P. Hayes

Daniel P. Hayes
Scientist
Radioactive Materials Division
Office of Radiological Health



550 First Avenue, New York, NY 10016
Radiation Safety Department, MSB G58
(212) 263-6888 Fax (212) 263-8581

Leandro Barreca
21st Century Oncology
12165 Metro Parkway, 19B
Fort Myers, Florida 33966

May 28, 2009

Dear Mr. Barreca,

This is to verify that Anurag Chandra, M.D. was an authorized user, as approved by our Medical Isotopes Committee, for remote afterloading brachytherapy (HDR). The broad license that covers this work is license number 75-2955-01, issued by the New York City Department of Health under the agreement state program of New York State. A copy of the license is attached.

Please contact me if you have further questions.

Sincerely,

A handwritten signature in black ink that reads "Steven R. Wagner".

Steven R. Wagner, MS, DABR, Director
Department of Radiation Safety
Radiation Safety Officer

**THE UNIVERSITY OF TEXAS
MD ANDERSON
CANCER CENTER****Department of Radiation Oncology – Unit 97
Phone: 713-792-2534 Fax: 713-563-8645**

June 16, 2009


To Whom It May Concern

This letter attests to the fact that Dr. Anurag Chandra has successfully completed a residency program at the University of Texas M. D. Anderson Cancer Center (UT MDACC). The UT MDACC radiation oncology residency program is approved by the Residency Review Committee of the ACGME. As part of this residency training program, Dr. Chandra has received training by an authorized user, a radiation oncologist listed on the UT MDACC license, and by an authorized medical physicist, a medical physicist listed on the UT MDACC license in:


1. Manual Brachytherapy
2. High Dose Rate remote afterloading using the Nucletron HDR device
3. Co-60 Gamma teletherapy units.

This training and experience has met or exceeded the training and experience requirements lists in paragraphs 35.490 and 35.690, including HDR device operation, safety procedures, and clinical use.

Sincerely,



Christopher H. Crane, M.D.
Associate Professor and Program Director
Residency Training Program
Radiation Oncology



Michael Gillin, Ph.D.
Deputy Chairman and Chief of Clinical Services
Radiation Physics

MG:td

CARING • INTEGRITY • DISCOVERY

1515 HOLCOMBE BOULEVARD • HOUSTON, TEXAS 77030-4009 • 713-792-2121 • www.mdanderson.org
A Comprehensive Cancer Center designated by the National Cancer Institute located in the Texas Medical Center

This is to acknowledge the receipt of your letter/application dated

6/18/09, and to inform you that the initial processing which includes an administrative review has been performed.

Amendment (09-31141-01)
There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

Please provide to this office within 30 days of your receipt of this card

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned **Mail Control Number** 143816.
When calling to inquire about this action, please refer to this control number.
You may call us on (610) 337-5398, or 337-5260.

NRC FORM 532 (R1)
(6-96)

Sincerely,
Licensing Assistance Team Leader